Equities research analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will announce earnings per share (EPS) of ($0.15) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Achillion Pharmaceuticals’ earnings, with estimates ranging from ($0.15) to ($0.14). Achillion Pharmaceuticals posted earnings of ($0.17) per share during the same quarter last year, which suggests a positive year over year growth rate of 11.8%. The firm is expected to announce its next earnings results on Thursday, February 28th.
According to Zacks, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.53) per share for the current financial year, with EPS estimates ranging from ($0.53) to ($0.52). For the next financial year, analysts expect that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.71) to ($0.66). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02.
A number of equities analysts have issued reports on ACHN shares. BidaskClub cut shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 18th. ValuEngine cut shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, December 18th. Finally, Zacks Investment Research cut shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company. Achillion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.17.
A number of institutional investors and hedge funds have recently bought and sold shares of ACHN. Point72 Asset Management L.P. acquired a new stake in shares of Achillion Pharmaceuticals during the third quarter worth $6,609,000. Nexthera Capital LP acquired a new stake in Achillion Pharmaceuticals in the 3rd quarter valued at $5,829,000. Assenagon Asset Management S.A. acquired a new stake in Achillion Pharmaceuticals in the 3rd quarter valued at $5,100,000. Dimensional Fund Advisors LP increased its stake in Achillion Pharmaceuticals by 14.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,892,184 shares of the biopharmaceutical company’s stock valued at $19,505,000 after buying an additional 849,721 shares during the last quarter. Finally, Marshall Wace North America L.P. increased its stake in Achillion Pharmaceuticals by 464.9% in the 3rd quarter. Marshall Wace North America L.P. now owns 820,146 shares of the biopharmaceutical company’s stock valued at $3,018,000 after buying an additional 674,956 shares during the last quarter. Institutional investors own 77.12% of the company’s stock.
ACHN stock traded up $0.02 during midday trading on Wednesday, reaching $2.14. The company’s stock had a trading volume of 36,714 shares, compared to its average volume of 3,025,738. Achillion Pharmaceuticals has a 52 week low of $1.29 and a 52 week high of $4.34. The stock has a market cap of $285.55 million, a PE ratio of -3.47 and a beta of 2.11.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Read More: What is a Leveraged Buyout (LBO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.